There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Cytek BioSciences Inc (CTKB) shows that investor sentiment remained same, with the stock’s consolidated last price to $4.96. The Cytek BioSciences Inc has recorded 6,813 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’.
This NASDAQ-listed company operates within the Medical Devices industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $4.96 and fluctuated between $4.9900 as its day high and $4.7000 as its day low. The current market capitalization of Cytek BioSciences Inc is $676.35M. A total of 1.14 million shares were traded on the day, compared to an average of 988.22K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, CTKB has seen 13 BUY and 19 SELL insider trades, representing the acquisition of 47,938 and the disposition of 2,373,665 shares. Over the last 12 months, there were 40 BUYs and 73 SELLs from insiders. Insiders purchased 160,424 shares during that period but sold 2,813,753.
In the most recent transaction, Jiang Wenbin sold 20,000 shares of CTKB for 4.34 per share on Nov 07. After the transaction, the President and CEO now owns 5,275,796 company shares. In a previous transaction on Oct 24, Jeanmonod Patrik sold 3,000 shares at 4.68 per share. CTKB shares that Chief Financial Officer owns now total 96,084.
Among the insiders who sold shares, Yan Ming disposed of 20,000 shares on Oct 19 at a per-share price of $4.80. This resulted in the Chief Technology Officer holding 7,775,962 shares of CTKB after the transaction. In another insider transaction, Jiang Wenbin sold 20,000 shares at $5.33 per share on Oct 09. Company shares held by the President and CEO now total 5,295,796.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CTKB in the last 3 months, the mean price target is $9.50 with high estimates of $12.00 and low estimates of $7.00. In terms of 52-week highs and lows, CTKB has a high of $15.17 and a low of $3.80.
As of this writing, CTKB has an earnings estimate of $0.04 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $0.06 per share and a lower estimate of $0.01. The company reported an EPS of $0.01 in the last quarter, which was -66.70% lower than expectations of $0.03.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CTKB’s latest balance sheet shows that the firm has $364.62M in Cash & Short Term Investments as of fiscal 2021. There were $2.77M in debt and $32.16M in liabilities at the time. Its Book Value Per Share was $3.07, while its Total Shareholder’s Equity was $406.80M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CTKB is Buy with a score of 4.20.